Life Sciences

  • September 11, 2026

    Tylenol Maker Seeks 2nd Circ. Relook In Autism, ADHD Suits

    Tylenol maker Kenvue and several retailers have urged the Second Circuit to revisit its decision overturning a district court's exclusion of expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD, saying the appeals court improperly restricted the trial court's "gatekeeping role."

  • September 11, 2026

    Exploding Home Sauna Suit Clears Damages Concerns

    A New Jersey woman will get to proceed with her product liability lawsuit claiming an at-home sauna spontaneously exploded, after a federal judge accepted Friday her argument that a jury could award her tens of millions of dollars, so the amount in controversy would not fall below the statutory minimum.

  • September 11, 2026

    AbbVie Seeks To Nix Health Orgs' 'New Theory' In 340B Row

    Two advocacy groups for safety net health providers shouldn't be allowed to argue that a D.C. federal court lacks jurisdiction over biopharmaceutical company AbbVie Inc.'s suit challenging the federal government's definition of a "patient" in the 340B drug discount program, AbbVie told the court.

  • September 11, 2026

    Abbott Can Move Baby Formula Death Suit Out Of Illinois

    An Illinois state appeals court on Friday ordered the dismissal of a product liability suit alleging Abbott Laboratories' Similac formula caused a premature Florida infant's fatal case of necrotizing enterocolitis, finding the case belongs in Florida rather than Chicago's Cook County.

  • September 11, 2026

    11th Circ. Backs $620K Award In Radiology Contract Fight

    The Eleventh Circuit upheld a $620,000 arbitration award in favor of an Indian teleradiology company against a radiology provider, finding the arbitrator did not exceed his authority by interpreting the parties' long-standing services agreement.

  • September 11, 2026

    Australian Bill Would Hone R&D Tax Credit To Newer Firms

    The Australian government is seeking input on a bill that would narrow eligibility for its research and development tax credit to newer firms while raising the value of the credit for businesses that qualify, the Department of the Treasury said Friday.

  • September 11, 2026

    Mass. Fund Says It Was Sidelined After Lining Up $300M

    A Massachusetts life sciences investment fund says SPRIM Global Investments strung it along on a pledge to bring it in as a co-general partner in a new joint fund, then backed out of the agreement and took control of the fund after the plaintiff lined up a $300 million investment, according to a lawsuit filed in Massachusetts state court.

  • September 11, 2026

    Fed. Circ. Questions Medical Training Co.'s $100M Deal Theory

    A medical training startup urged the Federal Circuit on Friday to revive claims accusing Galderma of a "classic catch-and-kill strategy" to derail what it says could have been a $100 million deal with Allergan, but a three-judge panel questioned whether that theory had been properly presented below.

  • September 11, 2026

    Fed. Circ. Agrees Globus Didn't Infringe Spinal Surgery IP

    The Federal Circuit on Friday upheld a Pennsylvania federal judge's decisions clearing Globus Medical Inc. of infringing Moskowitz Family LLC spinal surgery tool patents, agreeing that language used in the patents' opening statement, or preamble, limited their scope.

  • September 11, 2026

    REIT Defeats Class Claims Over $2.2B Property Impairments

    A California federal judge dismissed a proposed securities class action against Alexandria Real Estate Equities Inc., finding the investors didn't sufficiently allege that the REIT's executives misled them about $2.2 billion worth of property impairments.

  • September 10, 2026

    Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told

    Nektar Therapeutics' damages expert told a California federal jury on Thursday that Eli Lilly & Co. could owe the biotechnology company nearly $1 billion if it finds that the pharmaceutical giant breached a license agreement to co-develop Nektar's autoimmune-disease drug Rezpeg.

  • September 10, 2026

    Orthopedics Co. Investor Says Docs Hid 'Boys Club' Culture

    Terminated executives of Texas-based orthopedics company Orthofix Medical Inc. have been hit with a shareholder's derivative suit accusing them of damaging the company by attempting to conceal the culture of workplace harassment they perpetuated before and after a merger.

  • September 10, 2026

    RJ Reynolds Wants In On Suit Over FDA Vape Review Rule

    Vape and nicotine pouch subsidiaries owned by Altria and R.J. Reynolds are looking to upend the U.S. Food and Drug Administration's premarket authorization rule, claiming the agency is breaking the law by dragging out product reviews well past the statutory deadline, which delays their goods by years while illegal Chinese products flood the market.

  • September 10, 2026

    Clinical Trial Buyer Says Ex-Owner Breached $100M Deal

    Surge ECN Holdings LLC and ECN Operating LLC have accused the former owner of a clinical trial research network of violating a five-year noncompete and other restrictions tied to a deal worth more than $100 million, alleging he diverted customers, recruited key physicians and used confidential information to build a competing business.

  • September 10, 2026

    Apple Watch Ban In Masimo ITC Patent Case Hits High Court

    Apple Inc. has told the U.S. Supreme Court that the Federal Circuit improperly "lowered the bar" for meeting the U.S. International Trade Commission's domestic industry requirement in patent disputes, by affirming a decision that the Apple Watch infringed Masimo Corp. patents.

  • September 10, 2026

    Dompé To Pay $32M Over Foundation Co-Pay Kickback Claims

    The U.S. arm of Italian pharmaceutical company Dompé Farmaceutici SpA has agreed to pay $32 million to resolve allegations that it contributed funds to patient assistance foundations to induce purchases of its prescription eye drops Oxervate, the U.S. Department of Justice announced Thursday.

  • September 10, 2026

    Biosimilars Boast Big Savings But Face IP Risks, Report Says

    There are no biosimilar drugs in development for 90% of biologic products set to lose their patent exclusivity by 2034, according to a report released Thursday by the Association for Accessible Medicines, which warned that current patent policy threatens generic-drug development. 

  • September 10, 2026

    Squires Grants 10 Patent Reviews, Rejects None

    U.S. Patent and Trademark Office Director John Squires has instituted 10 more Patent Trial and Appeal Board petitions, largely in the pharmaceutical space.

  • September 10, 2026

    Colo. Judge Asked To Sanction Hospital In Gender Care Suit

    Transgender adolescent patients of Children's Hospital Colorado urged a state judge on Thursday to sanction the hospital for refusing to resume providing gender-affirming medical care for transgender youth patients, arguing that the hospital can't avoid its obligation to provide the care by blaming its providers.

  • September 10, 2026

    Patent Declaratory Judgment Actions Are Back In Vogue

    Companies facing threats of patent infringement lawsuits are increasingly embracing declaratory judgment actions, a trend attorneys attribute to two pro-patent-owner shifts: the low institution rate of Patent Trial and Appeal Board challenges and the growth of Amazon's internal patent dispute process.

  • September 10, 2026

    Judge Won't Touch Verdict In Blood Collection Patent Case

    A Delaware federal judge has denied a bid from medical equipment maker Kurin for a new trial after a jury found it owed Magnolia Medical $1.6 million for infringement of three patents covering blood culture collection products, saying the jury's verdict was not the product of confusion or a miscarriage of justice.

  • September 10, 2026

    PwC Will Pay $96M To Settle Valeant Investor Class Claims

    PricewaterhouseCoopers LLP has agreed to pay $96 million to end a long-running securities fraud suit over an alleged market manipulation scheme by Bausch predecessor Valeant Pharmaceuticals, the plaintiffs told a New Jersey federal court Thursday.

  • September 10, 2026

    Greenberg Traurig Sued Over Ex-Pharma CEO's Indictment

    Greenberg Traurig LLP devised the very business practices that got a former pharmaceutical CEO indicted for fraud and then billed the executive $1.4 million for defending the criminal case, according to a legal malpractice suit accusing the firm of an inherent conflict of interest.

  • September 10, 2026

    Indiana Justices Probe Timing Of Religious Abortion Suit

    Indiana justices sharply questioned both sides Thursday as they wrestled with whether the state's religious freedom law can be used to protect the abortion rights of Jewish women, repeatedly asking whether the case had developed enough to warrant a ruling.

  • September 10, 2026

    Frazier Life Sciences Adds $1.1B To Its Public Fund

    Healthcare-focused investment firm Frazier Life Sciences, advised by Kirkland & Ellis LLP, on Thursday revealed that it has closed on more than $1.1 billion of new capital commitments for its Public Fund.

Expert Analysis

  • Vanda Ruling Offers New Guide To Generic Labeling Disputes

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration is significant for its guidance on when generic-drug labeling remains sufficiently similar to brand labeling and when a difference requires a statutory exception, says Shashank Upadhye at Upadhye Tang.

  • Attorneys Using AI May Have Ethical Duty To Redact Docs

    Author Photo

    The trajectory of legal ethics guidance in recent years strongly suggests that as redaction technology becomes more accessible, the failure to use it when uploading highly confidential materials into artificial intelligence tools will become increasingly difficult to defend as reasonable, say attorneys at Lewis Brisbois.

  • Cannabis, Psychedelics Boom Raises IP Hurdles

    Author Photo

    Recent data regarding patent filing activity and litigation in the cannabis and psychedelics markets indicates that as commercial interest accelerates, the scope of publicly accessible prior art is also expanding, setting a higher bar for novelty and nonobviousness in patent applications, say attorneys at Sterne Kessler.

  • State AI Safety Laws Raise New Liabilities For Healthcare Cos.

    Author Photo

    Healthcare and life science companies using third-party artificial intelligence tools should pay particular attention to the changing state-level legal landscape, where the rollout of multiple AI safety laws is introducing both new compliance obligations and potential consumer protection liabilities, say attorneys at McDermott.

  • Series

    Juggling And Unicycling Make Me A Better Lawyer

    Author Photo

    Because I juggle (sometimes with fire) and ride the unicycle, friends and family used to joke that I should join the circus, but I pursued the practice of law instead and learned that my hobbies benefit my profession in several important ways, says Morgan Eddy at Smith Currie.

  • AI Note-Taking Suits May Fill Gap In Privacy Law Structure

    Author Photo

    A recent class action against Granola joins other pending lawsuits against AI note-taking providers, highlighting the legal uncertainty surrounding these tools, but there are practical steps companies using "invisible" AI services can take to mitigate risk, including conducting inventories and reviewing access permissions, say attorneys at Barnes & Thornburg.

  • FDA Closeout Letter Suggests Relaxing Stance On Wearables

    Author Photo

    The U.S. Food and Drug Administration's recent decision not to pursue enforcement action against Whoop's wearable blood pressure tracker, read together with guidance released earlier this year, suggests a softer shift in the FDA's approach to regulating wearables, say attorneys at Arnold & Porter.

  • Fed. Circ. Dental IP Ruling Reinforces Prior Art Framework

    Author Photo

    The Federal Circuit's recent decision in Dental Monitoring v. Align Technology reaffirms the necessity of substantive written description support for establishing an earlier effective prior art date under the America Invents Act, and aligns Patent Trial and Appeal Board practice with district court litigation, say attorneys at Morgan Lewis.

  • Justices' Hikma Reasoning May Extend Well Beyond Pharma

    Author Photo

    The active steps framework announced by the U.S. Supreme Court in its Hikma v. Amarin decision, finding that Amarin failed to plausibly allege inducement of infringement, has the potential to reshape how courts evaluate inducement claims across patent, copyright and other doctrines, say attorneys at BCLP.

  • Teva MDL Loss Shows DPAs Can Return To Haunt Civil Suits

    Author Photo

    Teva’s recent partial summary judgment loss in antitrust multidistrict litigation reinforces the importance of carefully scrutinizing any statement of facts a company admits to in a deferred prosecution agreement, and illustrates the potential costs of resolving a criminal investigation this way, say attorneys at Sheppard.

  • An Inside Look At Squires' Discretionary Denials

    Author Photo

    A deep dive into the discretionary denials issued by U.S. Patent and Trademark Office Director John Squires since he took over last year identifies trends in commonly asserted arguments and how they correlate with institution outcomes, say attorneys at Kirkland & Ellis.

  • Series

    Ballet Makes Me A Better Lawyer

    Author Photo

    A lifetime of learning and performing ballet taught me that success — whether in dance or practicing law — comes only through hours of thorough preparation, boundless energy and relentless effort, says Sharon Katz-Pearlman at Greenberg Traurig.

  • Fed. Circ. In July: Meeting The Enablement Requirement

    Author Photo

    The Federal Circuit's decision in Wyeth v. AstraZeneca last month exemplifies when a generalized conception of an invention is insufficient to enable the full scope of asserted patent infringement claims, and may lead to more enablement challenges, say attorneys at Knobbe Martens.

  • Series

    Taekwondo Makes Me A Better Lawyer

    Author Photo

    Taekwondo has taught me to recognize when to fight for a position and when to focus on finding a solution, and that the best outcomes are often achieved by solving problems — all of which has improved my work as a bankruptcy lawyer, mediator and Subchapter V trustee, says Amy Denton Mayer at Berger Singerman.

  • Why AI Diligence Is Especially Key In IP Practice

    Author Photo

    In light of recent federal court sanctions against intellectual property litigators for filing work product generated by artificial intelligence without verification, it's important to consider the unique risks and consequences that can arise from overreliance on AI, which poses less visible risks in IP matters, says Stephen Ball at Husch Blackwell.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here